Scholar Rock (NASDAQ:SRRK) Director Purchases $6,112,482.30 in Stock

Posted by Francis Steltz on Oct 27th, 2026

Scholar Rock Holding Corporation (NASDAQ:SRRK – Get Free Report) Director Srinivas Akkaraju purchased 146,970 shares of the stock in a transaction on Monday, October 26th. The stock was acquired at an average price of $41.59 per share, for a total transaction of $6,112,482.30. Following the completion of the purchase, the director directly owned 6,380,517 shares in the company, valued at approximately $265,365,702.03. The trade was a 2.36% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Srinivas Akkaraju also recently made the following trade(s):

On Friday, October 23rd, Srinivas Akkaraju acquired 142,500 shares of Scholar Rock stock. The shares were acquired at an average price of $41.32 per share, with a total value of $5,888,100.00.

Scholar Rock Price Performance

Shares of NASDAQ SRRK traded up $0.78 during mid-day trading on Tuesday, hitting $42.49. The company had a trading volume of 1,157,863 shares. The firm has a 50-day simple moving average of $49.17 and a two-hundred day simple moving average of $48.17. Scholar Rock Holding Corporation has a one year low of $27.07 and a one year high of $61.76.

Scholar Rock (NASDAQ:SRRK – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.84). During the same period last year, the company posted ($0.98) earnings per share. As a group, sell-side analysts predict that Scholar Rock Holding Corporation will post -3.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. JPMorgan Chase & Co. boosted their price target on Scholar Rock from $63.00 to $70.00 and gave the stock an “overweight” rating in a research report on Monday, September 21st. Truist Financial upped their price objective on Scholar Rock from $76.00 to $77.00 and gave the stock a “buy” rating in a research note on Thursday, September 24th. TD Cowen reissued a “buy” rating on shares of Scholar Rock in a report on Monday, September 14th. Citigroup raised their target price on shares of Scholar Rock from $60.00 to $74.00 and gave the company a “buy” rating in a research note on Monday, September 14th. Finally, Barclays cut shares of Scholar Rock from an “overweight” rating to a “cautious” rating in a research note on Tuesday, September 15th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.67.

Check Out Our Latest Research Report on Scholar Rock

Institutional Trading of Scholar Rock

A number of hedge funds have recently made changes to their positions in SRRK. BlackRock Inc. acquired a new position in shares of Scholar Rock in the second quarter valued at about $522,175,000. Redmile Group LLC increased its position in Scholar Rock by 73.7% during the first quarter. Redmile Group LLC now owns 9,066,621 shares of the company’s stock worth $445,715,000 after acquiring an additional 3,845,775 shares during the period. Jennison Associates LLC raised its stake in Scholar Rock by 19.5% in the 1st quarter. Jennison Associates LLC now owns 3,340,492 shares of the company’s stock worth $164,219,000 after purchasing an additional 545,304 shares in the last quarter. Jupiter Topco LLC acquired a new stake in Scholar Rock in the 2nd quarter worth about $123,279,000. Finally, Janus Henderson Group PLC boosted its holdings in Scholar Rock by 26.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,236,837 shares of the company’s stock valued at $109,891,000 after purchasing an additional 462,669 shares during the period. 91.08% of the stock is owned by institutional investors and hedge funds.

Scholar Rock Company Profile

(Get Free Report)

Scholar Rock, Inc is a biotechnology company focused on developing medicines that selectively target growth factors in the transforming growth factor beta (TGF-β) superfamily. The company’s research is intended to address serious diseases in which these signaling pathways play an important role, including neuromuscular and metabolic conditions.

Scholar Rock’s lead investigational product is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that limits muscle growth.